782TiP - Review of the management of advanced gastric cancer; an experience from a low resource setting

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Gastric Cancer
Presenter Kwamena Beecham
Authors K. Beecham1, V.D.N.K. Vanderpuye2, N.A. Adu-Aryee3
  • 1Radiotherapy, Korlebu Teaching Hospital, Accra/GH
  • 2Radiotherapy, Korlebu Teaching Hospital, GH- - Accra/GH
  • 3Surgery, Korlebu Teaching Hospital, Accra/GH



Adjuvant treatment combines Epirubicin, Cisplatin and 5-FU (ECF). Replacement of 5FU and Cisplatin with Capecitabine (X) and Oxaliplatin (O) has shown an efficacy similar to ECF, with improved tolerability and safety. The outcome of management of advanced gastric cancer at the Oncology Unit was assessed, with emphasis on the use of Capecitabine alone or in combination.

Patients & methods

27 patients adenocarcinoma of the stomach between 2004 and 2008 were eligible. Time to disease progression (TTP) as well as tolerability of treatment was assessed retrospectively.


Median follow up was 12 months (1 to 60 months). No adjuvant treatment was given in 36%.

26% received concurrent chemoradiation with Capecitabine. 11.1% received palliative radiotherapy only. One patient did not complete radiotherapy due to side effects. 26.6% received Capecitabine alone and combined with Oxaliplatin in 11.1% Grade 3/4 diarrhoea was reported in 7.4%; neuropathy and neutropenia were seen in 3.7%.

Median time to progression in patients who had adjuvant treatment was 6.4 months (2 to 13 months).


There is a favorable tolerability of Capecitabine used alone or in combination with radiotherapy or other chemotherapy drugs.


All authors have declared no conflicts of interest.